CJC-1295 research guide for Mutuáli. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Mutuáli trying to locate CJC-1295, the first thing to know is that this compound is distributed via specialist online vendors. What this means for Mutuáli researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those verification methods are available to every researcher. What consistently distinguishes top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety screening. This guide guides Mutuáli researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
CJC-1295 Mechanisms Explained
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Mutuáli studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Buying CJC-1295: Quality Markers to Look For
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor publish batch-specific COAs proactively? Suppliers that publish proactively are demonstrating research-grade standards. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are within acceptable research limits. Community reputation in research forums is a useful additional signal to COA verification — vendors with sustained positive community feedback have proved themselves through consistent results. For Mutuáli researchers making a first CJC-1295 purchase: work through this evaluation framework first, order conservatively at first, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Mutuáli
COA-verified · International tracking · Research grade
All use of CJC-1295 in Mutuáli or anywhere is research use only — this compound is not approved for human therapeutic use, and all handling should adhere to research compound handling standards. Storage requirements for CJC-1295: lyophilised powder at minus 20°C, reconstituted solution kept at 2-8°C refrigerated and consumed within 4 weeks; reconstitute only with bac water. Bacterial endotoxin contamination is the greatest safety hazard unique to this class of compound — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. Researchers combining CJC-1295 with other compounds should check the research literature for any reported interactions before beginning combination research.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
